Citation

Pandarakalam JP. Prog. Neurol. Psychiatry (2007) 2010; 14(1): 26-29.

Copyright

(Copyright © 2010, John Wiley and Sons)

DOI

10.1002/pnp.153

PMID

unavailable

Abstract

Although more quality research is required to inform clinical practice, serotonin-noradrenaline reuptake inhibitor - noradrenaline and specific serotonergic antidepressant (SNRI-NaSSA) combination therapy shows promise for treatment-resistant depression. Here, Dr Pandarakalam discusses the rationale behind the use of this combination and some of the evidence gained so far for its efficacy.

Language: en

Keywords

human; insomnia; depression; suicide attempt; anorexia; clinical practice; antidepressant agent; sexual dysfunction; mirtazapine; noradrenalin uptake inhibitor; serotonin uptake inhibitor; tricyclic antidepressant agent; venlafaxine; priority journal; note; drug mechanism; electroconvulsive therapy; mianserin; drug safety; drug potentiation; drug efficacy; diarrhea; nausea; side effect; duloxetine; serotonin syndrome; drug half life; liver injury; treatment response; serotonin 2A receptor; serotonin noradrenalin reuptake inhibitor; diastolic blood pressure; serotonin 2C receptor; serotonin 3A receptor